Telix Pharmaceuticals Limited (ASX: TLX) has announced a significant development in its journey towards transforming brain cancer diagnostics. The company has opened an Expanded Access Program (EAP) in the United States for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET), an investigational PET agent for imaging progressive or recurrent glioma. This move...
Telix pharmaceuticals is revolutionizing the way the world detects and treats cancer, it's ahead of schedule and is kicking goals left right and centre.
very exciting prospects for this one, was able to cover massive bullish ground pre-2019 during the XJO, XAO Australian All Ordinaries (and world wide indices) bearish turn.
Now sitting in what looks like the...
